Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
J Cardiovasc Electrophysiol ; 33(8): 1874-1879, 2022 08.
Article in English | MEDLINE | ID: covidwho-1886683


BACKGROUND: Fever is a potential side effect of the Covid-19 vaccination. Patients with Brugada syndrome (BrS) have an increased risk of life-threatening arrhythmias when experiencing fever. Prompt treatment with antipyretic drugs is suggested in these patients. AIM OF THE STUDY: To evaluate the incidence and management of fever within 48 h from Covid-19 vaccination among BrS patients. METHODS: One hundred sixty-three consecutive patients were enrolled in a prospective registry involving five European hospitals with a dedicated inherited disease ambulatory. RESULTS: The mean age was 50 ± 14 years and 121 (75%) patients were male. Prevalence of Brugada electrocardiogram (ECG) pattern type-1, -2, and -3 was 32%, 44%, and 24%, respectively. Twenty-eight (17%) patients had an implantable cardioverter-defibrillator (ICD). Fever occurred in 32 (19%) BrS patients after 16 ± 10 h from vaccination, with a peak of body temperature of 37.9° ± 0.5°. Patients with fever were younger (39 ± 13 vs. 48 ± 13 years, p = .04). No additional differences in terms of sex and cardiovascular risk factors were found between patients with fever and not. Twenty-seven (84%) out of 32 patients experienced mild fever and five (16%) moderate fever. Pharmacological treatment with antipyretic drugs was required in 18 (56%) out of 32 patients and was associated with the resolution of symptoms. No patient required hospital admission and no arrhythmic episode was recorded in patients with ICD within 48 h after vaccination. No induced type 1 BrS ECG pattern and new ECG features were found among patients with moderate fever. CONCLUSION: Fever is a common side effect in BrS patients after the Covid-19 vaccination. Careful evaluation of body temperature and prompt treatment with antipyretic drugs may be needed.

Antipyretics , Brugada Syndrome , COVID-19 Vaccines , COVID-19 , Defibrillators, Implantable , Adult , Antipyretics/adverse effects , Brugada Syndrome/diagnosis , Brugada Syndrome/epidemiology , Brugada Syndrome/therapy , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Electrocardiography , Female , Fever/chemically induced , Fever/diagnosis , Fever/epidemiology , Humans , Incidence , Male , Middle Aged , Vaccination/adverse effects
Clin Microbiol Infect ; 26(9): 1259.e5-1259.e7, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-597470


OBJECTIVE: It was recently suggested that ibuprofen might increase the risk for severe and fatal coronavirus disease 2019 (COVID-19) and should therefore be avoided in this patient population. We aimed to evaluate whether ibuprofen use in individuals with COVID-19 was associated with more severe disease, compared with individuals using paracetamol or no antipyretics. METHODS: In a retrospective cohort study of patients with COVID-19 from Shamir Medical Centre, Israel, we monitored any use of ibuprofen from a week before diagnosis of COVID-19 throughout the disease. Primary outcomes were mortality and the need for respiratory support, including oxygen administration and mechanical ventilation. RESULTS: The study included 403 confirmed cases of COVID-19, with a median age of 45 years. Of the entire cohort, 44 patients (11%) needed respiratory support and 12 (3%) died. One hundred and seventy-nine (44%) patients had fever, with 32% using paracetamol and 22% using ibuprofen, for symptom-relief. In the ibuprofen group, 3 (3.4%) patients died, whereas in the non-ibuprofen group, 9 (2.8%) patients died (p 0.95). Nine (10.3%) patients from the ibuprofen group needed respiratory support, compared with 35 (11%) from the non-ibuprofen group (p 1). When compared with exclusive paracetamol users, no differences were observed in mortality rates or the need for respiratory support among patients using ibuprofen. CONCLUSIONS: In this cohort of COVID-19 patients, ibuprofen use was not associated with worse clinical outcomes, compared with paracetamol or no antipyretic.

COVID-19 Drug Treatment , COVID-19/mortality , Fever/drug therapy , Ibuprofen/therapeutic use , Acetaminophen/adverse effects , Acetaminophen/therapeutic use , Adult , Antipyretics/adverse effects , Antipyretics/therapeutic use , Female , Fever/virology , Humans , Ibuprofen/adverse effects , Israel , Male , Middle Aged , Retrospective Studies
Am J Gastroenterol ; 115(8): 1153-1155, 2020 08.
Article in English | MEDLINE | ID: covidwho-525850

Coronavirus Infections/physiopathology , Digestive System Diseases/physiopathology , Pneumonia, Viral/physiopathology , Abdominal Pain/etiology , Abdominal Pain/metabolism , Abdominal Pain/physiopathology , Abdominal Pain/therapy , Ambulatory Care , Anorexia/etiology , Anorexia/metabolism , Anorexia/physiopathology , Anorexia/therapy , Anti-Bacterial Agents/adverse effects , Antipyretics/adverse effects , Antiviral Agents/adverse effects , Betacoronavirus , COVID-19 , Chemical and Drug Induced Liver Injury/etiology , Chemical and Drug Induced Liver Injury/metabolism , Chemical and Drug Induced Liver Injury/physiopathology , Chemical and Drug Induced Liver Injury/therapy , China , Clostridium Infections/diagnosis , Clostridium Infections/drug therapy , Coronavirus Infections/complications , Coronavirus Infections/metabolism , Coronavirus Infections/therapy , Diarrhea/etiology , Diarrhea/metabolism , Diarrhea/physiopathology , Diarrhea/therapy , Digestive System Diseases/etiology , Digestive System Diseases/metabolism , Digestive System Diseases/therapy , Endoscopy, Digestive System , Gastroenterology , Humans , Liver Diseases/etiology , Liver Diseases/metabolism , Liver Diseases/physiopathology , Liver Diseases/therapy , Nausea/etiology , Nausea/metabolism , Nausea/physiopathology , Nausea/therapy , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/metabolism , Pneumonia, Viral/therapy , Probiotics/therapeutic use , SARS-CoV-2 , Societies, Medical , Vomiting/etiology
Med Hypotheses ; 144: 109880, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-361316


Fever has been reported as a common symptom occurring in COVID-19 illness. Over the counter antipyretics such as ibuprofen and acetaminophen are often taken by individuals to reduce the discomfort of fever. Recently, the safety of ibuprofen in COVID-19 patients has been questioned due to anecdotal reports of worsening symptoms in previously healthy young adults. Studies show that ibuprofen demonstrates superior efficacy in fever reduction compared to acetaminophen. As fever may have benefit in shortening the duration of viral illness, it is plausible to hypothesize that the antipyretic efficacy of ibuprofen may be hindering the benefits of a fever response when taken during the early stages of COVID-19 illness.

Antipyretics/adverse effects , Antipyretics/therapeutic use , COVID-19 Drug Treatment , Fever/drug therapy , Ibuprofen/adverse effects , Ibuprofen/therapeutic use , Acetaminophen/therapeutic use , Fever/physiopathology , Humans , Models, Theoretical , Patient Safety , Treatment Outcome